Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 7Small Cell Lung Carcinoma 2Resectable Non-small Cell Lung Cancer 2Neoplasms 2Squamous-Cell Lung Cancer 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasm Metastasis 1NSCLC 1Melanoma 1Lymphatic Metastasis 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Bronchogenic 1Carcinoma 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 63Nivolumab 44atezolizumab 14Docetaxel 10Cyclophosphamide 10Paclitaxel 9Magnetic Resonance Spectroscopy 9Ipilimumab 9avelumab 8Specimen Handling 8durvalumab 7Radiosurgery 7Cetuximab 7spartalizumab 6Radiotherapy 6Immune Checkpoint Inhibitors 6Interleukin-2 5Carboplatin 5fludarabine 4cabozantinib 4Trastuzumab 4Sunitinib 4Psychiatric Rehabilitation 4Pemetrexed 4Oxaliplatin 4Fluorodeoxyglucose F18 4Everolimus 4Cisplatin 4Capecitabine 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Platinum Compounds × Thoracic × Clear all
NCT05614102 2026-03-31

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Bayer

Phase 1 Active not recruiting
284 enrolled
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡